anurajms/meta_analysis huggingface dataset:
MESH terms:
Open Mesh versus non‐Mesh for groin hernia repair
1. *Surgical Mesh; 2. Clinical Trials as Topic; 3. Hernia, Femoral [*surgery]; 4. Hernia, Inguinal [*surgery]; 5. Postoperative Complications [etiology]; 6. Secondary Prevention;
MESH terms:
Antioxidant supplementation for sickle cell disease
1. *Anemia, Sickle Cell [blood, drug therapy]; 2. *Antioxidants [therapeutic use]; 3. Ascorbic Acid [therapeutic use]; 4. Bias; 5. *Dietary Supplements; 6. Oxidative Stress [drug effects]; 7. Placebos [therapeutic use]; 8. Quality of Life; 9. *Randomized Controlled Trials as Topic;
MESH terms:
Nebuliser systems for drug delivery in cystic fibrosis
1. Anti-Bacterial Agents [therapeutic use]; 2. *Cystic Fibrosis [drug therapy]; 3. Nebulizers and Vaporizers; 4. Respiratory Aerosols and Droplets; 5. Saline Solution, Hypertonic [therapeutic use]; 6. Tobramycin [therapeutic use];
MESH terms:
Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis
1. *Cystic Fibrosis [complications]; 2. Exercise; 3. Physical Therapy Modalities; 4. Quality of Life; 5. Respiratory Therapy;
MESH terms:
Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis
1. *Cystic Fibrosis [therapy]; 2. Digital Technology; 3. Exercise; 4. Exercise Therapy; 5. Multicenter Studies as Topic; 6. Muscle Strength; 7. Quality of Life;
MESH terms:
Interventions for the long‐term prevention of hereditary angioedema attacks
1. Administration, Intravenous; 2. *Angioedemas, Hereditary [chemically induced, drug therapy, prevention & control]; 3. Complement C1 Inhibitor Protein [adverse effects, therapeutic use]; 4. Danazol [therapeutic use]; 5. Quality of Life; 6. Treatment Outcome;
MESH terms:
Strategies for screening for familial hypercholesterolaemia in primary care and other community settings
1. Bias; 2. *Hyperlipoproteinemia Type II [diagnosis, genetics, therapy]; 3. Interrupted Time Series Analysis; 4. Primary Health Care;
MESH terms:
Embolisation for pulmonary arteriovenous malformation
1. Arteriovenous Malformations [*therapy]; 2. Embolization, Therapeutic [adverse effects, *methods]; 3. Pulmonary Artery [*abnormalities]; 4. Pulmonary Veins [*abnormalities];
MESH terms:
Long‐acting inhaled bronchodilators for cystic fibrosis
1. Administration, Inhalation; 2. Adrenergic beta-2 Receptor Agonists [administration & dosage, *therapeutic use]; 3. Bronchodilator Agents [administration & dosage, *therapeutic use]; 4. Cystic Fibrosis [*drug therapy]; 5. Disease Progression; 6. Forced Expiratory Volume [drug effects]; 7. Muscarinic Antagonists [administration & dosage, *therapeutic use]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Time Factors; 11. Tiotropium Bromide [administration & dosage, *therapeutic use];
MESH terms:
Enzyme replacement therapy for infantile‐onset Pompe disease
1. Child Development; 2. Enzyme Replacement Therapy [adverse effects, *methods]; 3. Glycogen Storage Disease Type II [*drug therapy]; 4. Recombinant Proteins [adverse effects, therapeutic use]; 5. Respiration, Artificial [statistics & numerical data]; 6. alpha‐Glucosidases [*administration & dosage, adverse effects, deficiency];
MESH terms:
Beta‐blockers for preventing aortic dissection in Marfan syndrome
1. Adrenergic beta‐Antagonists [*therapeutic use]; 2. Aortic Dissection [etiology, mortality, *prevention & control]; 3. Marfan Syndrome [*complications]; 4. Propranolol [*therapeutic use];
MESH terms:
Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease
1. Assisted Circulation [statistics & numerical data]; 2. Cardiac Output, Low [etiology, mortality, *prevention & control]; 3. Cardiotonic Agents [*therapeutic use]; 4. Heart Defects, Congenital [mortality, *surgery]; 5. Hydrazones [*therapeutic use]; 6. Intensive Care Units, Pediatric [statistics & numerical data]; 7. Length of Stay [statistics & numerical data]; 8. Postoperative Complications [mortality, *prevention & control]; 9. Pyridazines [*therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Respiration, Artificial [statistics & numerical data]; 12. Simendan; 13. Syndrome;
MESH terms:
Non‐invasive ventilation for cystic fibrosis
1. *Sputum; 2. Cystic Fibrosis [*therapy]; 3. Masks; 4. Noninvasive Ventilation [*methods]; 5. Randomized Controlled Trials as Topic; 6. Respiratory Insufficiency [prevention & control];
MESH terms:
Non‐surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders
1. Blood Coagulation Disorders [complications, *drug therapy]; 2. Deamino Arginine Vasopressin [adverse effects, *therapeutic use]; 3. Hemostatics [adverse effects, *therapeutic use]; 4. Menorrhagia [*drug therapy, etiology]; 5. Randomized Controlled Trials as Topic; 6. Tranexamic Acid [adverse effects, *therapeutic use];
MESH terms:
Pneumococcal vaccines for cystic fibrosis
1. Cystic Fibrosis [*complications]; 2. Pneumococcal Infections [*prevention & control]; 3. Pneumococcal Vaccines [*therapeutic use];
MESH terms:
Intravenous alpha‐1 antitrypsin augmentation therapy for treating patients with alpha‐1 antitrypsin deficiency and lung disease
1. alpha 1-Antitrypsin [*administration & dosage]; 2. alpha 1-Antitrypsin Deficiency [complications, *drug therapy]; 3. Pulmonary Disease, Chronic Obstructive [*drug therapy, etiology]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Enzyme replacement therapy for Anderson‐Fabry disease
1. Enzyme Replacement Therapy [*methods]; 2. Fabry Disease [*drug therapy, enzymology]; 3. Isoenzymes [*administration & dosage]; 4. Pain Measurement; 5. Randomized Controlled Trials as Topic; 6. Recombinant Proteins; 7. Time Factors; 8. Trihexosylceramides [analysis, blood]; 9. alpha‐Galactosidase [*administration & dosage];
MESH terms:
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
1. Antiviral Agents [adverse effects, *therapeutic use]; 2. Cystic Fibrosis [*complications]; 3. Drug Administration Schedule; 4. Palivizumab [adverse effects, *therapeutic use]; 5. Pseudomonas aeruginosa; 6. Pseudomonas Infections [epidemiology]; 7. Randomized Controlled Trials as Topic; 8. Respiratory Syncytial Virus Infections [*drug therapy];
MESH terms:
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis‐related lung disease
1. Cystic Fibrosis [genetics, *therapy]; 2. Cystic Fibrosis Transmembrane Conductance Regulator [*genetics, therapeutic use]; 3. Gene Transfer Techniques; 4. Genetic Therapy [adverse effects, methods]; 5. Liposomes; 6. Randomized Controlled Trials as Topic; 7. Respiratory Function Tests; 8. Targeted Gene Repair [adverse effects, *methods];
MESH terms:
Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis
1. Cystic Fibrosis [*complications]; 2. Enzyme Inhibitors [*therapeutic use]; 3. Influenza, Human [*drug therapy]; 4. Neuraminidase [*antagonists & inhibitors];
MESH terms:
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
1. Drug Administration Schedule; 2. Enzyme Replacement Therapy [*methods]; 3. Iduronate Sulfatase [*administration & dosage]; 4. Mucopolysaccharidosis II [*drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Rare Diseases [*drug therapy, enzymology];
MESH terms:
Anti‐inflammatory drugs and analgesics for managing symptoms in people with cystic fibrosis‐related arthritis
1. Analgesics [*therapeutic use]; 2. Anti-Inflammatory Agents [*therapeutic use]; 3. Arthritis [*drug therapy, etiology]; 4. Cystic Fibrosis [*complications];
MESH terms:
Home versus hospital intravenous antibiotic therapy for cystic fibrosis
1. Anti-Bacterial Agents [*administration & dosage]; 2. Cystic Fibrosis [*complications]; 3. Home Care Services [*economics]; 4. Hospitalization [*economics]; 5. Injections, Intravenous; 6. Randomized Controlled Trials as Topic; 7. Respiratory Tract Infections [*drug therapy, etiology]; 8. Self Care; 9. Staphylococcal Infections [*drug therapy]; 10. Staphylococcus aureus;
MESH terms:
Ascorbic acid for the treatment of Charcot‐Marie‐Tooth disease
1. Ascorbic Acid [*therapeutic use]; 2. Charcot‐Marie‐Tooth Disease [*drug therapy, genetics]; 3. Randomized Controlled Trials as Topic;
MESH terms:
Oral steroids for long‐term use in cystic fibrosis
1. Administration, Oral; 2. Anti-Inflammatory Agents [*administration & dosage, adverse effects]; 3. Cystic Fibrosis [*complications]; 4. Early Termination of Clinical Trials; 5. Glucocorticoids [*administration & dosage, adverse effects]; 6. Growth [drug effects]; 7. Prednisolone [administration & dosage, adverse effects]; 8. Randomized Controlled Trials as Topic; 9. Respiratory Tract Diseases [*drug therapy, etiology]; 10. Sex Factors;
MESH terms:
Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis
1. Cystic Fibrosis [*complications, microbiology]; 2. Pseudomonas aeruginosa [immunology]; 3. Pseudomonas Infections [complications, *prevention & control]; 4. Pseudomonas Vaccines [adverse effects, *therapeutic use]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis
1. Anti‐Bacterial Agents [*administration & dosage, adverse effects]; 2. Cystic Fibrosis [*drug therapy, physiopathology]; 3. Disease Progression; 4. Injections, Intravenous; 5. Total Lung Capacity [physiology];
MESH terms:
Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease
1. Cardiac Output, Low [etiology, mortality, *prevention & control]; 2. Cardiotonic Agents [adverse effects, *therapeutic use]; 3. Dobutamine [therapeutic use]; 4. Heart Defects, Congenital [mortality, *surgery]; 5. Hydrazones [therapeutic use]; 6. Milrinone [adverse effects, *therapeutic use]; 7. Postoperative Complications [mortality, *prevention & control]; 8. Pyridazines [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Simendan; 11. Syndrome; 12. Time Factors;
MESH terms:
Surgical interventions for treating pectus excavatum
1. *Thoracic Surgery, Video‐Assisted [adverse effects]; 2. Funnel Chest [*surgery]; 3. Osteotomy [adverse effects, *methods]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Sodium channel blockers for cystic fibrosis
1. Amiloride [administration & dosage, *therapeutic use]; 2. Anti‐Bacterial Agents [administration & dosage]; 3. Cystic Fibrosis [*drug therapy, physiopathology]; 4. Forced Expiratory Volume [drug effects, physiology]; 5. Mucus [metabolism]; 6. Randomized Controlled Trials as Topic; 7. Respiration [*drug effects]; 8. Saline Solution, Hypertonic [administration & dosage]; 9. Sodium Channel Blockers [administration & dosage, *therapeutic use]; 10. Vital Capacity [drug effects, physiology];
MESH terms:
Vaccines for preventing influenza in people with cystic fibrosis
1. Cystic Fibrosis [*complications]; 2. *Influenza Vaccines [administration & dosage, adverse effects]; 3. Influenza, Human [*prevention & control]; 4. Randomized Controlled Trials as Topic; 5. Vaccines, Attenuated [administration & dosage, adverse effects]; 6. Vaccines, Inactivated [administration & dosage, adverse effects];
MESH terms:
Interventions for promoting physical activity in people with cystic fibrosis
1. *Cystic Fibrosis; 2. *Exercise; 3. *Motor Activity; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Time Factors;
MESH terms:
Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis
1. Acetylcysteine [*administration & dosage]; 2. Administration, Inhalation; 3. Administration, Oral; 4. Ambroxol [*administration & dosage]; 5. Carbocysteine [*administration & dosage]; 6. Cystic Fibrosis [complications, *drug therapy]; 7. Expectorants [*administration & dosage]; 8. Glutathione [administration & dosage]; 9. Lung Diseases [drug therapy]; 10. Mucociliary Clearance [drug effects]; 11. Nebulizers and Vaporizers; 12. Randomized Controlled Trials as Topic; 13. Saline Solution, Hypertonic [administration & dosage];
MESH terms:
Single‐incision sling operations for urinary incontinence in women
1. *Dyspareunia; 2. Pain; 3. Postoperative Complications; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. *Urinary Incontinence [surgery]; 7. *Urinary Incontinence, Stress [surgery]; 8. *Urinary Retention;
MESH terms:
Surgical approach to hysterectomy for benign gynaecological disease
1. *Abdominal Injuries; 2. Fever; 3. Hospitals; 4. *Hysterectomy [adverse effects];
MESH terms:
Combined oral contraceptive pill for primary dysmenorrhoea
1. Anti-Inflammatory Agents, Non-Steroidal [adverse effects]; 2. *Contraceptives, Oral, Combined [adverse effects]; 3. *Dysmenorrhea [drug therapy]; 4. Headache; 5. Muscle Cramp;
MESH terms:
Surgery for women with apical vaginal prolapse
1. *Dyspareunia; 2. Suspensions; 3. *Urinary Incontinence, Stress [etiology, surgery]; 4. *Uterine Prolapse [surgery];
MESH terms:
Statins for women with polycystic ovary syndrome not actively trying to conceive
1. *Acne Vulgaris [drug therapy]; 2. Contraceptives, Oral [therapeutic use]; 3. Hirsutism [drug therapy]; 4. *Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use]; 5. *Metformin [therapeutic use]; 6. *Polycystic Ovary Syndrome [complications, drug therapy]; 7. Testosterone [therapeutic use];
MESH terms:
Gonadotropin‐releasing hormone analogues for endometriosis
1. Calcium; 2. Calcium, Dietary; 3. Danazol [therapeutic use]; 4. *Drug-Related Side Effects and Adverse Reactions; 5. Dysmenorrhea; 6. *Dyspareunia [drug therapy, etiology]; 7. *Endometriosis [complications, drug therapy]; 8. Gestrinone; 9. Gonadotropin-Releasing Hormone; 10. Pelvic Pain [drug therapy, etiology]; 11. Progestins [therapeutic use];
MESH terms:
Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults
1. Cholinergic Antagonists [adverse effects]; 2. *Drug-Related Side Effects and Adverse Reactions; 3. Quality of Life; 4. Systematic Reviews as Topic; 5. Tolterodine Tartrate; 6. *Urinary Bladder, Overactive [drug therapy];
MESH terms:
Immediate versus delayed postpartum insertion of contraceptive implant and IUD for contraception
1. Contraception [methods]; 2. Contraceptive Agents; 3. *Intrauterine Devices; 4. Postpartum Period; 5. *Progestins; 6. Uterine Hemorrhage;
MESH terms:
Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency
1. *Amenorrhea; 2. Dydrogesterone; 3. Endometrium; 4. Estradiol; 5. Estrogens [adverse effects]; 6. *Menopause, Premature;
MESH terms:
Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use
1. Acetaminophen [therapeutic use]; 2. Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; 3. Dysmenorrhea [drug therapy, prevention & control]; 4. Ibuprofen [therapeutic use]; 5. *Intrauterine Devices, Medicated [adverse effects]; 6. Mefenamic Acid [therapeutic use]; 7. *Menorrhagia [drug therapy, etiology, prevention & control]; 8. Naproxen [therapeutic use]; 9. Thiamine [therapeutic use]; 10. *Tranexamic Acid [therapeutic use];
MESH terms:
Medical methods for first trimester abortion
1. *Abortifacient Agents, Nonsteroidal [adverse effects]; 2. *Abortion, Spontaneous [chemically induced]; 3. Diarrhea [chemically induced]; 4. Drug Therapy, Combination; 5. Estradiol; 6. Letrozole; 7. Methotrexate; 8. Mifepristone [adverse effects]; 9. *Misoprostol; 10. *Oxytocics; 11. Pregnancy Trimester, First; 12. Prostaglandins; 13. Tamoxifen;
MESH terms:
Immediate versus delayed postabortal insertion of contraceptive implant
1. *Abortifacient Agents; 2. *Abortion, Induced; 3. *Abortion, Spontaneous [epidemiology]; 4. Contraceptive Agents; 5. Pregnancy Rate; 6. Progestins;
MESH terms:
Treatment for recurrent vulvovaginal candidiasis (thrush)
1. Antifungal Agents [therapeutic use]; 2. *Candidiasis, Oral; 3. *Candidiasis, Vulvovaginal [drug therapy]; 4. Immunosuppressive Agents [therapeutic use];
MESH terms:
Surgical interventions for the management of chronic pelvic pain in women
1. *Chronic Pain [etiology, therapy]; 2. *Endometriosis; 3. *Laparoscopy; 4. Pelvic Pain [etiology, surgery]; 5. Quality of Life;
MESH terms:
Levonorgestrel‐releasing intrauterine device (LNG‐IUD) for symptomatic endometriosis following surgery
1. Dysmenorrhea; 2. *Endometriosis [drug therapy, surgery]; 3. Endometrium; 4. *Intrauterine Devices, Medicated; 5. Levonorgestrel;
MESH terms:
Ultrasound‐guided transvaginal ovarian needle drilling for clomiphene‐resistant polycystic ovarian syndrome in subfertile women
1. Clomiphene [therapeutic use]; 2. Fertility Agents, Female [therapeutic use]; 3. *Infertility, Female [drug therapy, etiology]; 4. Ovulation Induction; 5. *Polycystic Ovary Syndrome [complications]; 6. Pregnancy Rate; 7. Ultrasonography, Interventional;
MESH terms:
Pentoxifylline for the treatment of endometriosis‐associated pain and infertility  
1. *Endometriosis [complications, drug therapy]; 2. *Infertility, Female [drug therapy, etiology]; 3. Live Birth; 4. Pain; 5. *Pentoxifylline [adverse effects]; 6. Pregnancy Rate;
MESH terms:
Medical abortion offered in pharmacy versus clinic‐based settings
1. Abortion, Induced [adverse effects, standards, *statistics & numerical data]; 2. Ambulatory Care Facilities [*statistics & numerical data]; 3. Bias; 4. Health Services Accessibility [*statistics & numerical data]; 5. Nepal [epidemiology]; 6. Patient Satisfaction; 7. Pharmaceutical Services [standards, *statistics & numerical data]; 8. Postoperative Complications [epidemiology]; 9. Prospective Studies; 10. Puerperal Infection [epidemiology]; 11. Quality of Health Care [statistics & numerical data]; 12. Treatment Outcome;
MESH terms:
Selective oestrogen receptor modulators (SERMs) for endometriosis
1. Dysmenorrhea [etiology]; 2. Dyspareunia [etiology]; 3. Endometriosis [complications, *drug therapy, surgery]; 4. Pelvic Pain [drug therapy]; 5. Placebos [therapeutic use]; 6. Raloxifene Hydrochloride [*therapeutic use]; 7. Selective Estrogen Receptor Modulators [*therapeutic use];
MESH terms:
Dopamine agonists for preventing ovarian hyperstimulation syndrome
1. Abortion, Spontaneous [prevention & control]; 2. Administration, Oral; 3. Aminoquinolines [therapeutic use]; 4. Bromocriptine [therapeutic use]; 5. Cabergoline [therapeutic use]; 6. Dopamine Agonists [administration & dosage, *therapeutic use]; 7. Ergolines [therapeutic use]; 8. *Fertilization in Vitro; 9. Live Birth [epidemiology]; 10. Ovarian Hyperstimulation Syndrome [epidemiology, *prevention & control]; 11. Placebos [therapeutic use]; 12. Pregnancy Rate; 13. Randomized Controlled Trials as Topic; 14. Sperm Injections, Intracytoplasmic;
MESH terms:
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome
1. Abortion, Spontaneous [epidemiology, prevention & control]; 2. Bias; 3. Confidence Intervals; 4. *Fertilization in Vitro; 5. Hyperandrogenism [*drug therapy]; 6. Hyperinsulinism [*drug therapy]; 7. Hypoglycemic Agents [adverse effects, *therapeutic use]; 8. Live Birth [*epidemiology]; 9. Metformin [adverse effects, *therapeutic use]; 10. Ovarian Hyperstimulation Syndrome [epidemiology, prevention & control]; 11. Ovulation Induction [methods]; 12. Placebos [therapeutic use]; 13. Polycystic Ovary Syndrome [*complications]; 14. Pregnancy Rate; 15. Randomized Controlled Trials as Topic; 16. Sperm Injections, Intracytoplasmic;
MESH terms:
Progestogens or progestogen‐releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy)
1. Antineoplastic Agents, Hormonal [*administration & dosage]; 2. Bias; 3. Contraceptives, Oral [administration & dosage]; 4. Desogestrel [administration & dosage]; 5. Goserelin [administration & dosage]; 6. *Intrauterine Devices, Medicated; 7. Leiomyoma [*drug therapy, pathology]; 8. Leuprolide [administration & dosage]; 9. Levonorgestrel [administration & dosage]; 10. Lynestrenol [administration & dosage]; 11. Medroxyprogesterone Acetate [administration & dosage]; 12. Menstruation [drug effects]; 13. Nandrolone [administration & dosage, analogs & derivatives]; 14. Norethindrone Acetate [administration & dosage]; 15. Premenopause; 16. Progestins [*administration & dosage]; 17. Randomized Controlled Trials as Topic; 18. Tumor Burden [drug effects]; 19. Uterine Neoplasms [*drug therapy, pathology];
MESH terms:
Pessaries (mechanical devices) for managing pelvic organ prolapse in women
1. Bias; 2. Muscle Strength; 3. Pelvic Floor; 4. Pelvic Organ Prolapse [*therapy]; 5. *Pessaries [adverse effects]; 6. Randomized Controlled Trials as Topic; 7. Rectal Prolapse [therapy]; 8. Urethral Diseases [therapy]; 9. Urinary Bladder Diseases [therapy]; 10. Uterine Prolapse [therapy];
MESH terms:
Pre‐ and postsurgical medical therapy for endometriosis surgery
1. Bias; 2. Chemotherapy, Adjuvant [methods]; 3. Combined Modality Therapy [methods]; 4. Contraceptive Agents, Female [*therapeutic use]; 5. Endometriosis [*drug therapy, surgery]; 6. Estrogen Antagonists [*therapeutic use]; 7. Gonadotropin-Releasing Hormone [antagonists & inhibitors]; 8. Pain Measurement; 9. Pelvic Pain [prevention & control, therapy]; 10. Placebos [therapeutic use]; 11. Postoperative Care [methods]; 12. Pregnancy Rate; 13. Preoperative Care [methods]; 14. Randomized Controlled Trials as Topic; 15. Recurrence; 16. Secondary Prevention [*methods]; 17. Time Factors;
MESH terms:
Laparoscopic surgery for endometriosis
1. Antineoplastic Agents, Hormonal [therapeutic use]; 2. Denervation [methods]; 3. Electrocoagulation [methods]; 4. Endometriosis [complications, diagnosis, *surgery]; 5. Goserelin [therapeutic use]; 6. Helium [therapeutic use]; 7. Infertility, Female [etiology, *surgery]; 8. *Laparoscopy; 9. Pelvic Pain [etiology, surgery]; 10. Pregnancy Rate; 11. Randomized Controlled Trials as Topic; 12. Uterus [innervation];
MESH terms:
Surgical treatment for tubal disease in women due to undergo in vitro fertilisation
1. Abortion, Spontaneous [epidemiology]; 2. Fallopian Tube Diseases [*surgery]; 3. Fallopian Tubes [*surgery]; 4. *Fertilization in Vitro; 5. Pregnancy Outcome; 6. Pregnancy, Ectopic [epidemiology]; 7. Randomized Controlled Trials as Topic; 8. Salpingectomy [statistics & numerical data]; 9. Sperm Injections, Intracytoplasmic; 10. Sterilization, Tubal [statistics & numerical data];
MESH terms:
Tubal flushing for subfertility
1. Bias; 2. Contrast Media [chemistry, *therapeutic use]; 3. *Fallopian Tubes; 4. Infertility, Female [*therapy]; 5. Live Birth [epidemiology]; 6. Oils; 7. Pregnancy Rate; 8. Randomized Controlled Trials as Topic; 9. Solubility; 10. Therapeutic Irrigation [adverse effects, *methods]; 11. Water;
MESH terms:
Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia
1. Bias; 2. Contraceptive Agents, Female [*administration & dosage, adverse effects]; 3. Endometrial Hyperplasia [drug therapy, pathology, surgery]; 4. Hysterectomy [statistics & numerical data]; 5. Intrauterine Device Expulsion; 6. *Intrauterine Devices, Medicated [adverse effects]; 7. Levonorgestrel [*administration & dosage, adverse effects]; 8. Nausea [etiology]; 9. Patient Dropouts [statistics & numerical data]; 10. Patient Satisfaction [statistics & numerical data]; 11. Progestins [administration & dosage, adverse effects]; 12. Randomized Controlled Trials as Topic; 13. Remission Induction; 14. Time Factors; 15. Uterine Hemorrhage [etiology]; 16. Weight Gain;
MESH terms:
Oral versus intra‐vaginal imidazole and triazole anti‐fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)
1. Acute Disease; 2. Administration, Intravaginal; 3. Administration, Oral; 4. Antifungal Agents [*administration & dosage, economics]; 5. Azoles [*administration & dosage, economics]; 6. Bias; 7. Candidiasis, Vulvovaginal [*drug therapy]; 8. Cost-Benefit Analysis; 9. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for non‐tubal ectopic pregnancy
1. Abortifacient Agents, Nonsteroidal [administration & dosage, adverse effects]; 2. Bias; 3. Cesarean Section; 4. Chemoembolization, Therapeutic [adverse effects]; 5. Cicatrix [complications]; 6. Confidence Intervals; 7. Dilatation and Curettage [adverse effects, methods]; 8. Hysteroscopy; 9. Methotrexate [administration & dosage, adverse effects]; 10. Pregnancy, Ectopic [*therapy]; 11. Randomized Controlled Trials as Topic; 12. Sample Size; 13. Ultrasonography, Interventional; 14. Uterine Artery; 15. Uterine Artery Embolization [adverse effects]; 16. Vacuum Curettage;
MESH terms:
Progestogen‐releasing intrauterine systems for heavy menstrual bleeding
1. Antifibrinolytic Agents [administration & dosage, therapeutic use]; 2. Contraceptives, Oral [administration & dosage, therapeutic use]; 3. Endometrium [surgery]; 4. Hysterectomy; 5. *Intrauterine Devices, Medicated; 6. Levonorgestrel [administration & dosage, *therapeutic use]; 7. Mefenamic Acid [administration & dosage, therapeutic use]; 8. Menorrhagia [*drug therapy, surgery]; 9. Norethindrone [administration & dosage, *therapeutic use]; 10. Progesterone [administration & dosage, *therapeutic use]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Tranexamic Acid [administration & dosage, therapeutic use]; 14. Treatment Outcome;
MESH terms:
In‐bag manual versus uncontained power morcellation for laparoscopic myomectomy
1. Intraoperative Complications [etiology]; 2. Laparoscopy [adverse effects, *methods]; 3. Leiomyoma [*surgery]; 4. Length of Stay; 5. Morcellation [adverse effects, instrumentation, *methods]; 6. Operative Time; 7. Postoperative Complications [etiology]; 8. Randomized Controlled Trials as Topic; 9. Specimen Handling [instrumentation, methods]; 10. Uterine Myomectomy [adverse effects, *methods]; 11. Uterine Neoplasms [*surgery];
MESH terms:
Self‐administered versus provider‐administered medical abortion
1. *Patient Safety; 2. Abortifacient Agents [*administration & dosage]; 3. Abortion, Induced [*methods]; 4. Mifepristone [administration & dosage]; 5. Misoprostol [administration & dosage]; 6. Pregnancy Trimester, First; 7. Randomized Controlled Trials as Topic;
MESH terms:
Traditional suburethral sling operations for urinary incontinence in women
1. Randomized Controlled Trials as Topic; 2. *Suburethral Slings; 3. Urinary Incontinence [*surgery]; 4. Urinary Incontinence, Stress [*surgery]; 5. Urologic Surgical Procedures [economics, *methods];
MESH terms:
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome
1. Abortion, Spontaneous; 2. Birth Rate; 3. Body Mass Index; 4. Clomiphene [therapeutic use]; 5. Fertility Agents, Female [therapeutic use]; 6. Infertility, Female [therapy]; 7. Metformin [*therapeutic use]; 8. Ovary [surgery]; 9. Ovulation Induction [*methods]; 10. Polycystic Ovary Syndrome [*complications]; 11. Pregnancy Outcome; 12. Pregnancy Rate; 13. Randomized Controlled Trials as Topic;
MESH terms:
Laparoscopic colposuspension for urinary incontinence in women
1. Laparoscopy; 2. Quality of Life; 3. Randomized Controlled Trials as Topic; 4. Urethra; 5. Urinary Incontinence [*surgery]; 6. Urologic Surgical Procedures [*methods];
MESH terms:
Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis
1. *Fertilization in Vitro; 2. *Pregnancy Rate; 3. Abortion, Spontaneous [epidemiology]; 4. Endometriosis [*physiopathology]; 5. Gonadotropins [*agonists]; 6. Infertility, Female [etiology, *therapy]; 7. Ovulation Induction; 8. Pregnancy Outcome; 9. Pregnancy, Multiple; 10. Randomized Controlled Trials as Topic; 11. Sperm Injections, Intracytoplasmic;
MESH terms:
Exercise for dysmenorrhoea
1. Dysmenorrhea [*therapy]; 2. Exercise [*physiology]; 3. Fatigue [therapy]; 4. Menstruation; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Non‐steroidal anti‐inflammatory drugs for heavy menstrual bleeding
1. Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; 2. Contraceptives, Oral, Combined; 3. Dysmenorrhea [*drug therapy]; 4. Menorrhagia [*drug therapy]; 5. Naproxen [therapeutic use]; 6. Progesterone [administration & dosage]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for treating recurrent stress urinary incontinence after failed minimally invasive synthetic midurethral tape surgery in women
1. *Urologic Surgical Procedures; 2. Quality of Life; 3. Recurrence; 4. Suburethral Slings; 5. Treatment Failure; 6. Urinary Incontinence [*surgery]; 7. Urinary Incontinence, Stress [*surgery];
MESH terms:
Cyclical progestogens for heavy menstrual bleeding
1. Danazol [therapeutic use]; 2. *Intrauterine Devices, Medicated; 3. Medroxyprogesterone Acetate [therapeutic use]; 4. Menorrhagia [*drug therapy]; 5. Progesterone [administration & dosage, *therapeutic use]; 6. Progestins [therapeutic use]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Tranexamic Acid [therapeutic use];
MESH terms:
Antibiotic therapy for adults with neurosyphilis
1. Anti‐Bacterial Agents [*therapeutic use]; 2. Ceftriaxone [therapeutic use]; 3. Neurosyphilis [*drug therapy]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Robot‐assisted surgery in gynaecology
1. Genital Diseases, Female [*surgery]; 2. Genital Neoplasms, Female [*surgery]; 3. Hysterectomy [instrumentation, methods]; 4. Laparoscopy [instrumentation, *methods]; 5. Randomized Controlled Trials as Topic; 6. Robotic Surgical Procedures [*methods];
MESH terms:
Lifestyle changes in women with polycystic ovary syndrome
1. *Life Style; 2. Abdominal Fat [anatomy & histology]; 3. Exercise; 4. Insulin Resistance; 5. Obesity [complications, *therapy]; 6. Polycystic Ovary Syndrome [complications, *rehabilitation]; 7. Randomized Controlled Trials as Topic; 8. Virilism [therapy]; 9. Waist Circumference; 10. Weight Loss;
MESH terms:
Combined hormonal contraceptives for heavy menstrual bleeding
1. Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; 2. Contraceptive Agents, Female [adverse effects, *therapeutic use]; 3. Contraceptives, Oral, Combined [adverse effects, therapeutic use]; 4. Danazol [therapeutic use]; 5. Drug Therapy, Combination [methods]; 6. *Intrauterine Devices, Medicated; 7. Levonorgestrel [therapeutic use]; 8. Mefenamic Acid [therapeutic use]; 9. Menorrhagia [*drug therapy]; 10. Naproxen [therapeutic use]; 11. Nausea [chemically induced]; 12. Placebos [therapeutic use]; 13. Progestins [therapeutic use]; 14. Randomized Controlled Trials as Topic;
MESH terms:
Interventions to reduce shoulder pain following gynaecological laparoscopic procedures
1. Acetaminophen [therapeutic use]; 2. Analgesics [therapeutic use]; 3. Anti‐Inflammatory Agents, Non‐Steroidal [therapeutic use]; 4. Carbon Dioxide [administration & dosage]; 5. Diclofenac [therapeutic use]; 6. Drainage [adverse effects]; 7. Gynecologic Surgical Procedures [*adverse effects]; 8. Gynecological Examination [*adverse effects, methods]; 9. Incidence; 10. Insufflation [methods]; 11. Laparoscopy [*adverse effects, methods]; 12. Meperidine [therapeutic use]; 13. Pain Measurement; 14. Pain, Procedural [epidemiology, etiology, *prevention & control]; 15. Pirinitramide [therapeutic use]; 16. Pneumoperitoneum [surgery]; 17. Randomized Controlled Trials as Topic; 18. Shoulder Pain [epidemiology, etiology, *prevention & control];
MESH terms:
Endometrial resection and ablation techniques for heavy menstrual bleeding
1. Catheter Ablation; 2. Electrodes; 3. Endometrium [*surgery]; 4. Hysterectomy; 5. Laser Therapy; 6. Menorrhagia [*surgery]; 7. Operative Time; 8. Patient Satisfaction; 9. Postoperative Complications; 10. Randomized Controlled Trials as Topic;
MESH terms:
Gonadotrophins for ovulation induction in women with polycystic ovary syndrome
1. Abortion, Spontaneous [epidemiology]; 2. Birth Rate; 3. Clomiphene [therapeutic use]; 4. Drug Resistance; 5. Fertility Agents, Female [*therapeutic use]; 6. Follicle Stimulating Hormone [therapeutic use]; 7. Gonadotropins [*therapeutic use]; 8. Live Birth [epidemiology]; 9. Menotropins [therapeutic use]; 10. Ovarian Hyperstimulation Syndrome [chemically induced, epidemiology]; 11. Ovulation Induction [*methods]; 12. Polycystic Ovary Syndrome [*drug therapy]; 13. Pregnancy, Multiple [statistics & numerical data]; 14. Randomized Controlled Trials as Topic;
MESH terms:
Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women
1. Biofeedback, Psychology; 2. Exercise Therapy [*methods]; 3. Muscle Contraction [*physiology]; 4. *Pelvic Floor; 5. Perineum; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Urinary Incontinence [*rehabilitation]; 9. Urinary Incontinence, Stress [rehabilitation];
MESH terms:
Surgery for women with pelvic organ prolapse with or without stress urinary incontinence
1. Pelvic Organ Prolapse [*complications, *surgery]; 2. Randomized Controlled Trials as Topic; 3. *Suburethral Slings; 4. Surgical Mesh; 5. Urinary Incontinence, Stress [*complications];
MESH terms:
Acupuncture and acupressure for premenstrual syndrome
1. *Acupressure; 2. *Acupuncture Therapy; 3. *Quality of Life; 4. Luteal Phase [*psychology]; 5. Premenstrual Dysphoric Disorder [*therapy]; 6. Premenstrual Syndrome [*therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Oral contraceptives for pain associated with endometriosis
1. Contraceptives, Oral [*therapeutic use]; 2. Dysmenorrhea [*drug therapy]; 3. Endometriosis [complications, *drug therapy]; 4. Goserelin [therapeutic use]; 5. Pelvic Pain [*drug therapy, etiology]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Surgery for women with posterior compartment prolapse
1. Awareness; 2. Dyspareunia [epidemiology, surgery]; 3. Gynecologic Surgical Procedures [methods]; 4. Pelvic Organ Prolapse [*surgery]; 5. Postoperative Complications [epidemiology, surgery]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Reoperation [statistics & numerical data]; 9. Surgical Mesh; 10. Urinary Incontinence, Stress [epidemiology, surgery]; 11. Uterine Prolapse [surgery];
MESH terms:
Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
1. *Insulin Resistance; 2. *Live Birth; 3. Abortion, Spontaneous [epidemiology]; 4. Anovulation [*drug therapy]; 5. Clomiphene [therapeutic use]; 6. Hypoglycemic Agents [adverse effects, *therapeutic use]; 7. Infertility, Female [*drug therapy]; 8. Inositol [therapeutic use]; 9. Metformin [adverse effects, therapeutic use]; 10. Ovulation Induction [statistics & numerical data]; 11. Pioglitazone; 12. Polycystic Ovary Syndrome [*complications]; 13. Pregnancy Rate; 14. Randomized Controlled Trials as Topic; 15. Rosiglitazone; 16. Thiazolidinediones [therapeutic use];
MESH terms:
Preoperative medical therapy before surgery for uterine fibroids
1. Antineoplastic Agents, Hormonal [adverse effects, *therapeutic use]; 2. Blood Loss, Surgical; 3. Chemotherapy, Adjuvant [adverse effects]; 4. Dopamine Agonists [therapeutic use]; 5. Estrogen Antagonists [therapeutic use]; 6. Gonadotropin‐Releasing Hormone [*analogs & derivatives]; 7. Hysterectomy; 8. Leiomyoma [*drug therapy, surgery]; 9. Myometrium [surgery]; 10. Operative Time; 11. Preoperative Care [adverse effects, methods]; 12. Progestins [therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Uterine Neoplasms [blood, *drug therapy, surgery];
MESH terms:
Anterior vaginal repair for urinary incontinence in women
1. Gynecologic Surgical Procedures [adverse effects]; 2. Postoperative Complications [etiology]; 3. Randomized Controlled Trials as Topic; 4. Treatment Outcome; 5. Urinary Bladder [surgery]; 6. Urinary Incontinence [etiology, *surgery]; 7. Urinary Incontinence, Stress [etiology, surgery]; 8. Uterine Prolapse [surgery]; 9. Vagina [*surgery];
MESH terms:
Mid‐urethral sling operations for stress urinary incontinence in women
1. *Suburethral Slings [adverse effects]; 2. Pain, Postoperative [etiology]; 3. Postoperative Complications [etiology]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Reoperation [statistics & numerical data]; 7. Urethra [injuries]; 8. Urinary Bladder [injuries]; 9. Urinary Incontinence, Stress [*surgery]; 10. Urologic Surgical Procedures [adverse effects, *methods];
MESH terms:
Open retropubic colposuspension for urinary incontinence in women
1. *Suburethral Slings; 2. Gynecologic Surgical Procedures [*methods]; 3. Randomized Controlled Trials as Topic; 4. Suture Techniques; 5. Urinary Incontinence [*surgery]; 6. Urinary Incontinence, Stress [surgery]; 7. Urologic Surgical Procedures [*methods]; 8. Vagina [surgery];
MESH terms:
Bladder neck needle suspension for urinary incontinence in women
1. *Needles; 2. *Suture Techniques; 3. Randomized Controlled Trials as Topic; 4. Recurrence; 5. Urethra [*surgery]; 6. Urinary Bladder [*surgery]; 7. Urinary Incontinence, Stress [*surgery]; 8. Urologic Surgical Procedures [methods]; 9. Vagina [surgery];
MESH terms:
Progesterone receptor modulators for endometriosis
1. Danazol [therapeutic use]; 2. Dysmenorrhea [drug therapy, epidemiology]; 3. Dyspareunia [drug therapy, epidemiology]; 4. Endometriosis [*drug therapy]; 5. Estrenes [therapeutic use]; 6. Gestrinone [adverse effects, therapeutic use]; 7. Gonadotropin‐Releasing Hormone [analogs & derivatives]; 8. Hormone Antagonists [administration & dosage, adverse effects, *therapeutic use]; 9. Leuprolide [adverse effects, therapeutic use]; 10. Mifepristone [administration & dosage, adverse effects, *therapeutic use]; 11. Norpregnadienes [therapeutic use]; 12. Oximes [therapeutic use]; 13. Prevalence; 14. Randomized Controlled Trials as Topic; 15. Receptors, Progesterone [*antagonists & inhibitors];
MESH terms:
Antibiotic prophylaxis for elective hysterectomy
1. Anti-Bacterial Agents [*therapeutic use]; 2. *Antibiotic Prophylaxis; 3. Antiprotozoal Agents [therapeutic use]; 4. Bacterial Infections [*prevention & control]; 5. Cephalosporins [therapeutic use]; 6. Elective Surgical Procedures [*adverse effects]; 7. Fever [epidemiology]; 8. Hysterectomy [*adverse effects, methods]; 9. Lincosamides [therapeutic use]; 10. Pelvis; 11. Penicillins [therapeutic use]; 12. Postoperative Complications [*prevention & control]; 13. Randomized Controlled Trials as Topic; 14. Sulfonamides [therapeutic use]; 15. Urinary Tract Infections [epidemiology, prevention & control];
MESH terms:
Selective progesterone receptor modulators (SPRMs) for uterine fibroids
1. Amenorrhea [drug therapy]; 2. Antineoplastic Agents, Hormonal [*therapeutic use]; 3. Estrenes [*therapeutic use]; 4. Leiomyoma [*drug therapy]; 5. Leuprolide [therapeutic use]; 6. Menstruation [drug effects]; 7. Mifepristone [*therapeutic use]; 8. Norpregnadienes [*therapeutic use]; 9. Oximes [*therapeutic use]; 10. Pelvic Pain [drug therapy]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Receptors, Progesterone [*antagonists & inhibitors]; 14. Uterine Neoplasms [*drug therapy];
MESH terms:
Washout policies in long‐term indwelling urinary catheterisation in adults
1. *Catheters, Indwelling [statistics & numerical data]; 2. Device Removal; 3. Equipment Failure; 4. Randomized Controlled Trials as Topic; 5. Solutions [*administration & dosage, chemistry]; 6. Therapeutic Irrigation [adverse effects, *methods]; 7. Time Factors; 8. Urinary Bladder Neck Obstruction [therapy]; 9. Urinary Catheterization [*instrumentation]; 10. Urinary Incontinence [therapy];
MESH terms:
Surgery for tubal infertility
1. Fallopian Tube Diseases [*surgery]; 2. Fallopian Tubes [*surgery]; 3. Fertilization in Vitro; 4. Infertility, Female [*surgery]; 5. Watchful Waiting;
MESH terms:
Nonsteroidal anti‐inflammatory drugs for pain in women with endometriosis
1. Anti-Inflammatory Agents, Non-Steroidal [*therapeutic use]; 2. Endometriosis [complications, *drug therapy]; 3. Pain [*drug therapy, etiology];
MESH terms:
Long‐term hormone therapy for perimenopausal and postmenopausal women
1. *Perimenopause; 2. *Postmenopause; 3. Cardiovascular Diseases [chemically induced, mortality]; 4. Cause of Death; 5. Estrogen Replacement Therapy [*adverse effects, methods]; 6. Estrogens [*adverse effects, therapeutic use]; 7. Hot Flashes [drug therapy]; 8. Neoplasms [chemically induced, mortality]; 9. Progesterone [*adverse effects, therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Venous Thromboembolism [chemically induced];
MESH terms:
Surgery for women with anterior compartment prolapse
1. Cystocele [surgery]; 2. Gynecologic Surgical Procedures [methods]; 3. Pelvic Organ Prolapse [prevention & control, *surgery]; 4. Randomized Controlled Trials as Topic; 5. Rectal Prolapse [surgery]; 6. Secondary Prevention; 7. Surgical Mesh; 8. Suture Techniques; 9. Urinary Incontinence [surgery]; 10. Uterine Prolapse [surgery];
MESH terms:
Interventions for preventing and treating incontinence‐associated dermatitis in adults
1. Administration, Topical; 2. Amitriptyline [administration & dosage]; 3. Dermatitis [etiology, prevention & control, *therapy]; 4. Dermatologic Agents [*administration & dosage]; 5. Fecal Incontinence [*complications]; 6. Petrolatum [administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Skin Care [methods]; 9. Skin Cream [administration & dosage]; 10. Soaps [administration & dosage]; 11. Urinary Incontinence [*complications]; 12. Zinc Oxide [administration & dosage];
MESH terms:
Short‐term and long‐term effects of tibolone in postmenopausal women
1. Breast Neoplasms [chemically induced, prevention & control]; 2. Dyspareunia [drug therapy]; 3. Estrogen Receptor Modulators [adverse effects, *therapeutic use]; 4. Estrogen Replacement Therapy [adverse effects, *methods]; 5. Hot Flashes [*drug therapy]; 6. Neoplasm Recurrence, Local [chemically induced]; 7. Norpregnenes [adverse effects, *therapeutic use]; 8. Postmenopause [*drug effects]; 9. Randomized Controlled Trials as Topic; 10. Stroke [chemically induced]; 11. Sweating [drug effects]; 12. Uterine Hemorrhage [chemically induced];
MESH terms:
Antibiotic treatment for the sexual partners of women with bacterial vaginosis
1. *Secondary Prevention; 2. *Sexual Partners; 3. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 4. Clindamycin [therapeutic use]; 5. Indazoles [therapeutic use]; 6. Lincosamides [therapeutic use]; 7. Metronidazole [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Time Factors; 11. Tinidazole [therapeutic use]; 12. Vaginosis, Bacterial [*prevention & control];
MESH terms:
Techniques for the interruption of tubal patency for female sterilisation
1. *Surgical Instruments [adverse effects]; 2. Electrocoagulation [*methods]; 3. Randomized Controlled Trials as Topic; 4. Salpingectomy [*methods]; 5. Sterilization, Tubal [adverse effects, instrumentation, *methods];
MESH terms:
Bioidentical hormones for women with vasomotor symptoms
1. Estradiol [adverse effects, *therapeutic use]; 2. Estrogens [adverse effects, *therapeutic use]; 3. Estrogens, Conjugated (USP) [adverse effects, *therapeutic use]; 4. Hot Flashes [*drug therapy]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Policies for replacing long‐term indwelling urinary catheters in adults
1. Age Factors; 2. Anti-Infective Agents, Local; 3. Antibiotic Prophylaxis; 4. *Catheters, Indwelling; 5. Chlorhexidine; 6. Decision Making; 7. Device Removal [methods, *standards]; 8. Health Policy; 9. Pharmaceutical Solutions; 10. Randomized Controlled Trials as Topic; 11. Sex Factors; 12. Time Factors; 13. Urinary Catheterization [methods, *standards]; 14. *Urinary Catheters; 15. Urinary Tract Infections [*prevention & control];
MESH terms:
Antibiotics for treating septic abortion
1. Abortion, Septic [*drug therapy]; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Cephalothin [therapeutic use]; 4. Chloramphenicol [therapeutic use]; 5. Clindamycin [therapeutic use]; 6. Drug Therapy, Combination; 7. Kanamycin [therapeutic use]; 8. Length of Stay; 9. Penicillins [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Tetracycline [therapeutic use];
MESH terms:
Chinese herbal medicine for menopausal symptoms
1. Drugs, Chinese Herbal [adverse effects, *therapeutic use]; 2. Estazolam [therapeutic use]; 3. Fluoxetine [therapeutic use]; 4. Hormone Replacement Therapy; 5. Hot Flashes [drug therapy]; 6. Menopause; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Sweating [*drug effects]; 10. Time Factors;
MESH terms:
Tricyclic and related drugs for nocturnal enuresis in children
1. Antidepressive Agents, Tricyclic [adverse effects, *therapeutic use]; 2. Clinical Alarms; 3. Enuresis [*drug therapy]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Trocar types in laparoscopy
1. *Patient Safety; 2. Abdominal Injuries [etiology]; 3. Equipment Design [adverse effects]; 4. Hernia, Abdominal [etiology]; 5. Laparoscopy [adverse effects, *instrumentation]; 6. Pain, Postoperative [prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Surgical Instruments [*adverse effects]; 9. Vascular System Injuries [*etiology]; 10. Viscera [*injuries];
MESH terms:
Urethral (indwelling or intermittent) or suprapubic routes for short‐term catheterisation in hospitalised adults
1. Asymptomatic Infections; 2. Bacteriuria [etiology]; 3. Catheters, Indwelling [*adverse effects, *standards]; 4. Drainage; 5. Randomized Controlled Trials as Topic; 6. Urinary Catheterization [adverse effects, *methods, standards]; 7. Urinary Tract Infections [etiology, prevention & control];
MESH terms:
Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women
1. Combined Modality Therapy [methods]; 2. Electric Stimulation Therapy; 3. Exercise Therapy [*methods]; 4. Hot Temperature [therapeutic use]; 5. *Pelvic Floor; 6. Pessaries; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Treatment Outcome; 10. Urinary Incontinence, Stress [*therapy]; 11. Urinary Incontinence, Urge [*therapy];
MESH terms:
Hormonal and intrauterine methods for contraception for women aged 25 years and younger
1. *Contraceptives, Oral, Combined; 2. *Intrauterine Devices; 3. Administration, Topical; 4. Contraception [*methods]; 5. Contraceptive Agents, Female; 6. Intrauterine Devices, Copper; 7. Levonorgestrel; 8. Randomized Controlled Trials as Topic; 9. Time Factors;
MESH terms:
Nonsteroidal anti‐inflammatory drugs for dysmenorrhoea
1. Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects, *therapeutic use]; 2. Cyclooxygenase Inhibitors [adverse effects, therapeutic use]; 3. Dysmenorrhea [*drug therapy]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for pain with intrauterine device insertion
1. Anti‐Inflammatory Agents, Non‐Steroidal [therapeutic use]; 2. Ibuprofen [therapeutic use]; 3. Intrauterine Devices [*adverse effects]; 4. Lidocaine [therapeutic use]; 5. Misoprostol [therapeutic use]; 6. Naproxen [therapeutic use]; 7. Oxytocics [therapeutic use]; 8. Pain [*drug therapy, prevention & control]; 9. Prilocaine [therapeutic use]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Doctors or mid‐level providers for abortion
1. Abortifacient Agents; 2. Abortion, Legal [*adverse effects, education, standards]; 3. Abortion, Therapeutic [*adverse effects, education, standards]; 4. Allied Health Personnel [education, *standards]; 5. Clinical Competence [*standards]; 6. Cohort Studies; 7. Midwifery [education, standards]; 8. Mifepristone; 9. Misoprostol; 10. Nurses [*standards]; 11. Nursing Assistants [education, standards]; 12. Observational Studies as Topic; 13. Physician Assistants [education, standards]; 14. Physicians [*standards]; 15. Pregnancy Trimester, First; 16. Randomized Controlled Trials as Topic; 17. Vacuum Curettage [adverse effects];
MESH terms:
Immediate postpartum insertion of intrauterine device for contraception
1. *Intrauterine Devices; 2. *Postpartum Period; 3. Contraception, Barrier [instrumentation, *methods]; 4. Feasibility Studies; 5. Randomized Controlled Trials as Topic; 6. Time Factors;
MESH terms:
Invasive urodynamic studies for the management of lower urinary tract symptoms (LUTS) in men with voiding dysfunction
1. Decision Making; 2. Lower Urinary Tract Symptoms [*physiopathology, *therapy]; 3. Outcome Assessment, Health Care; 4. Randomized Controlled Trials as Topic; 5. Urination [physiology]; 6. Urination Disorders [*physiopathology, *therapy]; 7. Urodynamics [physiology];